<DOC>
	<DOCNO>NCT02489916</DOCNO>
	<brief_summary>The investigator clinical trial ( patient metastatic colorectal cancer treat donafenib failure standard therapy ) ass safety efficacy donafenib patient metastatic colorectal cancer , progress approve standard therapy .</brief_summary>
	<brief_title>Donafenib Monotherapy Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study multicentre , phase 1B study recruit 47 patient 6 site . Patients eligible participate histological cytological documentation adenocarcinoma colon rectum . They must receive locally currently approve standard therapy disease progression within 3 month last administration last standard therapy stop standard therapy unacceptable toxic effect . The available standard therapy include many follow licensed : fluoropyrimidine , oxaliplatin , irinotecan , bevacizumab ; cetuximab panitumumab patient KRAS wild-type tumour . Patients age 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; life expectancy least 3 month ; adequate bone-marrow , liver , renal function start trial . Patients could participate previously receive sorafenib uncontrolled medical disorder . All patient receive best supportive care , exclude investigational antitumour agent antineoplastic chemotherapy , hormonal therapy , immunotherapy . Patients receive oral donafenib 300mg ( CM4307 ) 4 week cycle disease progression , death , unacceptable toxic effect , withdrawal consent patient , decision treat physician discontinuation would patient 's best interest.The primary endpoint safety.The second endpoint progression-free survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Have histological cytological documentation adenocarcinoma colon rectum ; Have receive locally currently approve standard therapy disease progression within 3 month last administration last standard therapy stop standard therapy unacceptable toxic effect . Standard therapies include many follow licensed : fluoropyrimidine , oxaliplatin , irinotecan , bevacizumab ; cetuximab panitumumab patient KRAS wildtype tumour ; Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Life expectancy least 3 month ; Have adequate bonemarrow , liver , renal function start trial . Prothrombin time international normalized ratio≤2；or prothrombin time≤16 second ; activate partial thromboplastin time ( APTT ) ≤43 second ; TT≤21 second . Patients prior treatment sorafenib ; Patients Central nervous system ( CNS ) involvement ; patient uncontrolled medical disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>CM4307</keyword>
	<keyword>Previously treat metastatic colorectal cancer</keyword>
</DOC>